Using ER-positive BC cell lines, two studies showed in vitro that a combination of treatment with PI3K and CDK4/6 inhibitors can overcome resistance to single-agent CDK4/6 inhibitor, because of the downregulation of cyclin D1 [79,81]. The gene discussed is CDK4; the disease is breast cancer.